Lv11
10 积分 2023-02-16 加入
Rare cutaneous adverse reactions associated with GLP-1 agonists: a review of the published literature
1小时前
待确认
Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial
2小时前
已完结
Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial
2小时前
已完结
Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models
19天前
已完结
FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions
21天前
已完结
Fibroblast growth factor receptors, developmental corruption and malignant disease
21天前
已完结
The Klotho proteins in health and disease
21天前
已完结
Pharmacological Characterization of Apraglutide, a Novel Long-Acting Peptidic Glucagon-Like Peptide-2 Agonist, for the Treatment of Short Bowel Syndrome
25天前
已完结
Therapeutic Potential of GLP-2 Analogs in Gastrointestinal Disorders: Current Knowledge, Nutritional Aspects, and Future Perspectives
26天前
已完结
S-nitrosylated GAPDH initiates apoptotic cell death by nuclear translocation following Siah1 binding
27天前
已完结
皖公网安备34019202002308
